The European Society of Cardiology (ESC) Congress 2026 took place in Munich from August 28 to 31, with new clinical trial results presented across cardiovascular disease. From major phase 3 successes and failures to earlier-stage programs, we selected some of the readouts that stood out to us. Aficamten succeeds in non-obstructive HCM Cytokinetics’ aficamten has become the first … Read more
August wasn’t the busiest month for biopharmas and life science companies on the deals front, but it did see sustained research collaboration in oncology and metabolic disease. As per usual, American companies were the most eager dealmakers, followed by biotechs located in the Asia Pacific region. Top biotech M&As of August 2026 Despite the holiday … Read more
The life science industry in Sweden is the cornerstone of the Swedish economy, as it is the second largest export sector in the region. Nordic Life Science Days being held in Stockholm, Sweden, echoes the growing role of collaboration in healthcare in Sweden, and in the Nordics at large. This week, biotech, pharma and healthtech … Read more
David Bailey has rejoined STAAR after participating in the successful campaign to block Alcon’s takeover of the company. Source link
The Centers for Medicare and Medicaid Services’ policy update extends Medicare coverage to severe aortic stenosis patients without symptoms, a change that analysts said will especially benefit Edwards Lifesciences. Source link
Companies including Tempus AI and Updoc are tasked with building an agentic AI system for managing heart failure. Source link
CEO Mike Mahoney gave more details at a Thursday investor conference, saying the company likely lost orders while its plants and distribution centers were shut down. Source link
CFO Preston Wells said at a healthcare conference that the company is still working through supply issues in its peripheral vascular business and had fewer hip sales than expected so far this quarter. Source link
Analysts called the acquisition a good fit for Axogen but said the company’s plans to finance the deal with a public stock offering could be a point of contention for investors. Source link
The company promoted three executives and eliminated a fourth position as part of changes intended to support its ongoing commercial transformation. Source link